BioLineRx Ltd. (TLV:BLRX)
1.500
0.00 (0.00%)
May 14, 2026, 5:10 PM IDT
BioLineRx Employees
As of December 31, 2025, BioLineRx had 24 total employees, including 20 full-time and 4 part-time employees. The number of employees decreased by 4 or -14.29% compared to the previous year.
Employees
24
Change (1Y)
-4
Growth (1Y)
-14.29%
Revenue / Employee
170.99K ILS
Profits / Employee
-170.27K ILS
Market Cap
39.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | -4 | -14.29% | 20 | 4 |
| Dec 31, 2024 | 28 | -51 | -64.56% | 24 | 4 |
| Dec 31, 2023 | 79 | 30 | 61.22% | 79 | 0 |
| Dec 31, 2022 | 49 | 11 | 28.95% | 49 | 0 |
| Dec 31, 2021 | 38 | 0 | - | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Bonus BioGroup | 42 |
| Matricelf | 15 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Geffen Residence & Renewal | 6 |
| Can-Fite BioPharma | 5 |
| BioLight Life Sciences | 4 |
BioLineRx News
- 16 days ago - BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1 - TheFly
- 16 days ago - BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 5 weeks ago - BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial - GuruFocus
- 5 weeks ago - BioLineRx, Hemispherian initiate clinical trial of GLIX1 - TheFly
- 5 weeks ago - Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma - Business Wire
- 7 weeks ago - BioLineRx initiates Phase 1/2a study of GLIX1 - TheFly
- 7 weeks ago - BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 7 weeks ago - BioLineRx Earnings Call Transcript: Q4 2025 - Transcripts